JP2005531321A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005531321A5 JP2005531321A5 JP2004518691A JP2004518691A JP2005531321A5 JP 2005531321 A5 JP2005531321 A5 JP 2005531321A5 JP 2004518691 A JP2004518691 A JP 2004518691A JP 2004518691 A JP2004518691 A JP 2004518691A JP 2005531321 A5 JP2005531321 A5 JP 2005531321A5
- Authority
- JP
- Japan
- Prior art keywords
- aldolase
- gene expression
- nephrotoxicity
- value
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000014509 gene expression Effects 0.000 claims description 134
- 108090000623 proteins and genes Proteins 0.000 claims description 92
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 claims description 91
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 claims description 91
- 238000000034 method Methods 0.000 claims description 78
- 231100000417 nephrotoxicity Toxicity 0.000 claims description 78
- 206010029155 Nephropathy toxic Diseases 0.000 claims description 65
- 230000007694 nephrotoxicity Effects 0.000 claims description 65
- 102000003780 Clusterin Human genes 0.000 claims description 54
- 108090000197 Clusterin Proteins 0.000 claims description 54
- 239000003795 chemical substances by application Substances 0.000 claims description 49
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 47
- 108010036949 Cyclosporine Proteins 0.000 claims description 47
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 47
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 47
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 46
- 229960001265 ciclosporin Drugs 0.000 claims description 46
- 108010028310 Calbindin 1 Proteins 0.000 claims description 41
- 101000868455 Rattus norvegicus Solute carrier organic anion transporter family member 1A3 Proteins 0.000 claims description 41
- 210000005084 renal tissue Anatomy 0.000 claims description 41
- 102000016838 Calbindin 1 Human genes 0.000 claims description 39
- 102000004264 Osteopontin Human genes 0.000 claims description 26
- 108010081689 Osteopontin Proteins 0.000 claims description 26
- 210000003734 kidney Anatomy 0.000 claims description 24
- 239000003550 marker Substances 0.000 claims description 24
- 102100036037 Podocin Human genes 0.000 claims description 17
- 101710162479 Podocin Proteins 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 229940000406 drug candidate Drugs 0.000 claims description 14
- 208000024891 symptom Diseases 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 108020004999 messenger RNA Proteins 0.000 claims description 12
- 230000001988 toxicity Effects 0.000 claims description 12
- 231100000419 toxicity Toxicity 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 10
- 230000006698 induction Effects 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- 229940127089 cytotoxic agent Drugs 0.000 claims description 8
- 239000002254 cytotoxic agent Substances 0.000 claims description 8
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 6
- 230000001629 suppression Effects 0.000 claims description 6
- 230000031018 biological processes and functions Effects 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 101150009126 C4 gene Proteins 0.000 claims description 4
- 230000003589 nefrotoxic effect Effects 0.000 claims description 4
- 231100000381 nephrotoxic Toxicity 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 238000013518 transcription Methods 0.000 claims description 4
- 230000035897 transcription Effects 0.000 claims description 4
- 108010028778 Complement C4 Proteins 0.000 claims description 3
- 231100000050 cytotoxic potential Toxicity 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 230000003907 kidney function Effects 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 238000002493 microarray Methods 0.000 claims description 3
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 2
- 108010018360 alpha 2u globulin Proteins 0.000 claims description 2
- 210000003292 kidney cell Anatomy 0.000 claims description 2
- 201000006370 kidney failure Diseases 0.000 claims description 2
- 230000004043 responsiveness Effects 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims 36
- 101710185991 Hepatitis A virus cellular receptor 1 homolog Proteins 0.000 claims 36
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 33
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 33
- 101000613820 Homo sapiens Osteopontin Proteins 0.000 claims 27
- 102100040557 Osteopontin Human genes 0.000 claims 27
- 231100000252 nontoxic Toxicity 0.000 claims 5
- 230000003000 nontoxic effect Effects 0.000 claims 5
- 230000003321 amplification Effects 0.000 claims 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims 4
- 230000001668 ameliorated effect Effects 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 231100000433 cytotoxic Toxicity 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 3
- 238000003786 synthesis reaction Methods 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 2
- 101150084418 EGF gene Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 238000000636 Northern blotting Methods 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 238000011529 RT qPCR Methods 0.000 claims 2
- 102000006382 Ribonucleases Human genes 0.000 claims 2
- 108010083644 Ribonucleases Proteins 0.000 claims 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 229940126575 aminoglycoside Drugs 0.000 claims 2
- 238000004458 analytical method Methods 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 229930182912 cyclosporin Natural products 0.000 claims 2
- 230000003013 cytotoxicity Effects 0.000 claims 2
- 231100000135 cytotoxicity Toxicity 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 238000003757 reverse transcription PCR Methods 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 claims 2
- 150000003456 sulfonamides Chemical class 0.000 claims 2
- 229960001967 tacrolimus Drugs 0.000 claims 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 2
- IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 claims 2
- 229960004453 trimethadione Drugs 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 238000002651 drug therapy Methods 0.000 claims 1
- 238000010195 expression analysis Methods 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 230000001338 necrotic effect Effects 0.000 claims 1
- 150000002891 organic anions Chemical class 0.000 claims 1
- 238000010998 test method Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000005239 tubule Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 238000009736 wetting Methods 0.000 claims 1
- 229930105110 Cyclosporin A Natural products 0.000 description 45
- 241000700159 Rattus Species 0.000 description 29
- 230000008859 change Effects 0.000 description 16
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 16
- 101800003838 Epidermal growth factor Proteins 0.000 description 14
- 102400001368 Epidermal growth factor Human genes 0.000 description 14
- 229940116977 epidermal growth factor Drugs 0.000 description 14
- 239000000523 sample Substances 0.000 description 13
- 230000000875 corresponding effect Effects 0.000 description 11
- -1 KIM-1 Proteins 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 101150076211 TH gene Proteins 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 206010061481 Renal injury Diseases 0.000 description 3
- 208000037806 kidney injury Diseases 0.000 description 3
- 101150017040 I gene Proteins 0.000 description 2
- 102000013519 Lipocalin-2 Human genes 0.000 description 2
- 108010051335 Lipocalin-2 Proteins 0.000 description 2
- 206010062237 Renal impairment Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101150034814 F gene Proteins 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000755935 Mus musculus Fructose-bisphosphate aldolase B Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000003064 k means clustering Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100001095 no nephrotoxicity Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0215509.1A GB0215509D0 (en) | 2002-07-04 | 2002-07-04 | Marker genes |
| PCT/EP2003/007111 WO2004005544A2 (en) | 2002-07-04 | 2003-07-03 | Marker genes for determining renal toxicity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009233624A Division JP2010042019A (ja) | 2002-07-04 | 2009-10-07 | マーカー遺伝子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005531321A JP2005531321A (ja) | 2005-10-20 |
| JP2005531321A5 true JP2005531321A5 (enExample) | 2006-08-17 |
Family
ID=9939850
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004518691A Pending JP2005531321A (ja) | 2002-07-04 | 2003-07-03 | マーカー遺伝子 |
| JP2009233624A Pending JP2010042019A (ja) | 2002-07-04 | 2009-10-07 | マーカー遺伝子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009233624A Pending JP2010042019A (ja) | 2002-07-04 | 2009-10-07 | マーカー遺伝子 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20060008804A1 (enExample) |
| EP (2) | EP1925677A3 (enExample) |
| JP (2) | JP2005531321A (enExample) |
| CN (1) | CN1688715A (enExample) |
| AU (1) | AU2003250879B2 (enExample) |
| BR (1) | BR0312405A (enExample) |
| CA (1) | CA2493860A1 (enExample) |
| GB (1) | GB0215509D0 (enExample) |
| IL (1) | IL165883A0 (enExample) |
| WO (1) | WO2004005544A2 (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004500879A (ja) | 2000-06-16 | 2004-01-15 | バイオジェン インコーポレイテッド | 腎の調節エレメントおよびそれらの使用方法 |
| DK1401869T3 (da) | 2001-06-01 | 2008-04-28 | Biogen Idec Inc | Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1 |
| CA2512138C (en) | 2002-12-30 | 2013-07-16 | Biogen Idec Ma Inc. | Kim-1 antagonists and use to modulate immune system |
| US20050272101A1 (en) * | 2004-06-07 | 2005-12-08 | Prasad Devarajan | Method for the early detection of renal injury |
| CA2565701A1 (en) * | 2004-05-06 | 2005-11-17 | Jonathan M. Barasch | Ngal for reduction and amelioration of ischemic and nephrotoxic injuries |
| DK1831699T3 (da) * | 2004-12-20 | 2010-03-15 | Antibodyshop As | Bestemmelse af neutrofil gelatine-associeret lipocalin (NGAL) som en diagnostisk markør for nyresygdomme |
| EP1865985B1 (en) | 2005-03-02 | 2010-08-25 | Biogen Idec MA Inc. | Kim-1 antibodies for treatment of th2-mediated conditions |
| US20070037232A1 (en) * | 2005-03-31 | 2007-02-15 | Barasch Jonathan M | Detection of NGAL in chronic renal disease |
| US20070087387A1 (en) | 2005-04-21 | 2007-04-19 | Prasad Devarajan | Method for the Early Detection of Renal Disease Using Proteomics |
| US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
| US20080090304A1 (en) * | 2006-10-13 | 2008-04-17 | Barasch Jonathan Matthew | Diagnosis and monitoring of chronic renal disease using ngal |
| PL2035835T3 (pl) * | 2006-05-30 | 2012-05-31 | Antibodyshop As | Sposoby szybkiej oceny ciężkości urazu |
| WO2008017306A1 (en) * | 2006-08-07 | 2008-02-14 | Antibodyshop A/S | Diagnostic test to exclude significant renal injury |
| EP2137538B1 (en) * | 2007-03-21 | 2014-04-09 | Bioporto Diagnostics A/s | Diagnostic test for renal injury |
| EP2479571A3 (en) | 2007-03-26 | 2012-09-26 | Novartis AG | Predictive renal safety biomarkers and biomarker signatures to monitor kidney function |
| US20090104649A1 (en) | 2007-06-11 | 2009-04-23 | Garovic Vesna D | Markers for preeclampsia |
| US8846036B2 (en) | 2007-10-19 | 2014-09-30 | Abbott Laboratories | Antibodies that bind to mammalian NGAL and uses thereof |
| EP2215481B2 (en) * | 2007-11-15 | 2017-01-18 | Bioporto Diagnostics A/S | Diagnostic use of individual molecular forms of a biomarker |
| EP2075343A1 (en) * | 2007-12-21 | 2009-07-01 | Gert Mayer | A method of diagnosing a progressive disease |
| US8338096B2 (en) * | 2008-04-15 | 2012-12-25 | Rainer Oberbauer | Markers of acute kidney failure |
| US7977110B2 (en) | 2008-06-02 | 2011-07-12 | Children's Hospital Medical Center | Method for distinguishing between kidney dysfunctions |
| ES2341419B1 (es) * | 2008-08-14 | 2011-05-03 | Hospital Clinic I Provincial De Barcelona | Wnt1 como biomarcador de daño renal. |
| WO2010054025A1 (en) * | 2008-11-05 | 2010-05-14 | Abbott Laboratories | Neutrophil gelatinase-associated lipocalin (ngal) protein isoforms enriched from urine and recombinant chinese hamster ovary (cho) cells and related compositions, antibodies, and methods of enrichment, analysis and use |
| CN104330574B (zh) * | 2008-11-10 | 2017-04-12 | 阿斯图特医药公司 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
| EP2364370B1 (en) * | 2008-11-22 | 2014-09-03 | Astute Medical, Inc. | Methods for prognosis of acute renal failure |
| EP2379752B1 (fr) * | 2009-01-19 | 2015-09-30 | Biomérieux S.A. | Procedes pour determiner la susceptibilite a contracter une infection nosocomiale chez un patient et pour etablir un pronostic d'evolution d'un syndrome septique |
| DK2391653T3 (en) * | 2009-01-28 | 2015-02-09 | Ind Tech Res Inst | Biomarkers associated nephropathy |
| WO2011017685A1 (en) * | 2009-08-07 | 2011-02-10 | Rules-Based Medicine, Inc. | Methods and devices for detecting kidney transplant rejection |
| ES2530866T3 (es) | 2009-12-21 | 2015-03-06 | Mayo Foundation | Marcador temprano de proteinuria en pacientes tratados con un tratamiento anti-VEGF |
| US9476868B2 (en) | 2009-12-23 | 2016-10-25 | Hill's Pet Nutrition, Inc. | Compositions and methods for diagnosing and treating kidney disorders in a canine |
| JP2013529907A (ja) | 2010-05-24 | 2013-07-25 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | Ｎｇａｌタンパク質変異体及びその使用 |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2857499A1 (en) | 2010-10-01 | 2015-04-08 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| JP5804629B2 (ja) * | 2011-07-29 | 2015-11-04 | 株式会社メディクローム | 遺伝子発現変動解析による化学物質の毒性評価方法 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2845117A1 (en) * | 2011-09-14 | 2013-03-21 | Basf Se | Means and methods for assessing kidney toxicity |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| AU2013334276B2 (en) | 2012-10-24 | 2019-07-04 | ProKidney IPCo, LLC | Renal cell populations and uses thereof |
| EP2925337B1 (en) | 2012-11-21 | 2019-07-03 | The Trustees of Columbia University in the City of New York | Mutant ngal proteins and uses thereof |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10420337B2 (en) | 2013-03-15 | 2019-09-24 | Lifeline Scientific, Inc. | Transporter with a glucose sensor for determining viability of an organ or tissue |
| US10077439B2 (en) | 2013-03-15 | 2018-09-18 | Modernatx, Inc. | Removal of DNA fragments in mRNA production process |
| WO2014182330A1 (en) | 2013-05-06 | 2014-11-13 | Hitachi Chemical Company Ltd | Devices and methods for capturing target molecules |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| WO2015153860A1 (en) * | 2014-04-04 | 2015-10-08 | Somalogic, Inc. | Glomerular filtration rate biomarkers and uses thereof |
| WO2015160805A1 (en) * | 2014-04-15 | 2015-10-22 | The Brigham And Women's Hospital, Inc. | Circulating kim-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney |
| US10712349B2 (en) | 2014-04-15 | 2020-07-14 | The Brigham And Women's Hospital, Inc. | Circulating KIM-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney |
| US10801066B2 (en) | 2014-09-05 | 2020-10-13 | American University Of Beirut | Determination of risk for development of cardiovascular disease by measuring urinary levels of podocin and nephrin messenger RNA |
| WO2016077537A1 (en) * | 2014-11-12 | 2016-05-19 | Hitachi Chemical Co., Ltd. | Method and device for diagnosing organ injury |
| WO2016208776A1 (ja) | 2015-06-25 | 2016-12-29 | 株式会社国際電気通信基礎技術研究所 | 多器官連関システムを基盤とした予測装置、及び予測プログラム |
| JP6624704B2 (ja) | 2015-08-31 | 2019-12-25 | 日立化成株式会社 | 尿路上皮疾患の評価のための分子法 |
| CN114594268A (zh) | 2016-03-29 | 2022-06-07 | 无限生物制药公司 | 用以预防或治疗肾脏疾病的活性组分的候选物质的筛选装置和筛选方法 |
| JP6332780B2 (ja) | 2016-03-29 | 2018-05-30 | 株式会社国際電気通信基礎技術研究所 | 医薬組成物又は食品組成物、及び有効成分の体内での効果の評価方法 |
| EP3472347B1 (en) * | 2016-06-17 | 2023-01-04 | F. Hoffmann-La Roche AG | In vitro nephrotoxicity screening assay |
| US12174201B2 (en) | 2017-10-12 | 2024-12-24 | Cedars-Sinai Medical Center | Prognosis and progression biomarkers for chronic kidney disease |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA951461B (en) * | 1994-02-22 | 1996-01-24 | Univ Illinois | Genes and genetic elements associated with sensitivity to platimun-based drugs |
| US6586389B1 (en) * | 1998-01-22 | 2003-07-01 | Administrators Of The Tulane Educational Fund | Cubilin protein, DNA sequences encoding cubilin and uses thereof |
| CA2340589A1 (en) * | 1998-08-28 | 2000-03-09 | Incyte Pharmaceuticals, Inc. | Toxicological response markers |
| WO2000047761A2 (en) * | 1999-02-12 | 2000-08-17 | Phase-1 Molecular Toxicology, Inc. | High-throughput toxicological testing using cultured organisms and cells |
| US20010034023A1 (en) * | 1999-04-26 | 2001-10-25 | Stanton Vincent P. | Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing |
| AU1466001A (en) * | 1999-11-05 | 2001-05-14 | Phase-1 Molecular Toxicology | Methods of determining individual hypersensitivity to an agent |
| US20020037508A1 (en) * | 2000-01-19 | 2002-03-28 | Michele Cargill | Human single nucleotide polymorphisms |
| AU2001275346A1 (en) * | 2000-06-05 | 2001-12-17 | General Hospital Corporation | Compositions, kits, and methods for identification and modulation of type i diabetes |
| JP2004500879A (ja) * | 2000-06-16 | 2004-01-15 | バイオジェン インコーポレイテッド | 腎の調節エレメントおよびそれらの使用方法 |
| EP1356093A2 (en) * | 2000-06-21 | 2003-10-29 | Hitachi Chemical Co., Ltd. | Gene markers for lung cancer |
| AU2001271998A1 (en) * | 2000-07-13 | 2002-01-30 | The Johns Hopkins University School Of Medicine | Detection and treatment of polycystic kidney disease |
| AU2001281322A1 (en) * | 2000-07-13 | 2002-01-30 | Biogen, Inc. | Methods of identifying renal protective factors |
| JP2004522411A (ja) * | 2000-07-31 | 2004-07-29 | ジーン ロジック インコーポレイテッド | 分子毒性学モデリング |
| DE10056802B4 (de) * | 2000-11-14 | 2005-06-16 | Epigenomics Ag | Verfahren zur Detektion von Methylierungszuständen zur toxikologischen Diagnostik |
| CA2440008A1 (en) * | 2001-01-29 | 2002-08-29 | Phase-1 Molecular Toxicology, Inc. | Rat toxicologically relevant genes and uses thereof |
-
2002
- 2002-07-04 GB GBGB0215509.1A patent/GB0215509D0/en not_active Ceased
-
2003
- 2003-07-03 CN CNA038187833A patent/CN1688715A/zh active Pending
- 2003-07-03 JP JP2004518691A patent/JP2005531321A/ja active Pending
- 2003-07-03 EP EP07119607A patent/EP1925677A3/en not_active Withdrawn
- 2003-07-03 US US10/518,575 patent/US20060008804A1/en not_active Abandoned
- 2003-07-03 WO PCT/EP2003/007111 patent/WO2004005544A2/en not_active Ceased
- 2003-07-03 CA CA002493860A patent/CA2493860A1/en not_active Abandoned
- 2003-07-03 AU AU2003250879A patent/AU2003250879B2/en not_active Ceased
- 2003-07-03 EP EP03762612A patent/EP1521847A2/en not_active Withdrawn
- 2003-07-03 BR BR0312405-3A patent/BR0312405A/pt not_active IP Right Cessation
-
2004
- 2004-12-20 IL IL16588304A patent/IL165883A0/xx unknown
-
2009
- 2009-10-07 JP JP2009233624A patent/JP2010042019A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003250879B2 (en) | Marker genes for determining renal toxicity | |
| US8329410B2 (en) | Method for diagnosing kidney disease comprising detecting the level of annexin A2 | |
| CN111876478B (zh) | 肺结节诊断标志物及应用 | |
| KR20160045547A (ko) | 췌장암 진단용 조성물 및 이를 이용한 췌장암 진단방법 | |
| Park et al. | RNA‐seq profiling of tubulointerstitial tissue reveals a potential therapeutic role of dual anti‐phosphatase 1 in glomerulonephritis | |
| DE60219809T2 (de) | Verbindungen und Verfahren zur Nachweiss von Karzinomen und deren Vorstufen | |
| JP2008512984A5 (enExample) | ||
| KR102328932B1 (ko) | 신장이식 후 항체 매개성 거부반응의 진단 또는 예측을 위한 소변 엑소좀 바이오마커 | |
| US20110236396A1 (en) | Methods and compositions for diagnosing and treating a colorectal adenocarcinoma | |
| KR20220039065A (ko) | 대장암에 대한 항암제 감수성 예측을 위한 신규 바이오마커 | |
| JP2020522501A (ja) | Ｔ−ｄｍ１による癌治療成績の予測方法 | |
| KR20200070177A (ko) | 암의 진단용 조성물 | |
| KR102771306B1 (ko) | 전립선암의 예후 예측용 조성물 | |
| US20050009030A1 (en) | Histone deacetylase: novel molecular target of neurotoxicity | |
| Cheval et al. | Plasticity of mouse renal collecting duct in response to potassium depletion | |
| EP1791974A2 (en) | Biomarkers for acute graft rejection | |
| KR102535150B1 (ko) | 암의 예후 예측용 조성물 | |
| KR20110117674A (ko) | ＩｇＡ 신증의 예측 방법 및 ＩｇＡ 신증 환자의 선택 방법 | |
| CN110241217A (zh) | 早期诊断胰腺癌的分子标记 | |
| KR102954554B1 (ko) | 근감소증 진단용 조성물 및 이를 이용한 근감소증 진단 방법 | |
| KR102039816B1 (ko) | 신장이식 후 이식 장기의 섬유증 진단 또는 예측용 바이오마커 | |
| US20020055117A1 (en) | Methods for detecting prostate cancer | |
| KR102259695B1 (ko) | 대장암에 대한 항암제 감수성 예측을 위한 신규 바이오마커 | |
| KR102350228B1 (ko) | 신장이식 후 t세포 매개성 거부반응의 진단 또는 예측을 위한 소변 엑소좀 바이오마커 | |
| KR20220126661A (ko) | 췌장암의 진단용 조성물 |